Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Foralumab in Severe COVID-19
NCT04983446Phase 2Withdrawn
- Sponsor
- Tiziana Life Sciences
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of foralumab in coronavirus disease 2019 (COVID-19), COVID-19 pneumonia, sponsored by Tiziana Life Sciences. Planned start Apr 2022; status: withdrawn.
02
Drugs
foralumab
03
Conditions
coronavirus disease 2019 (COVID-19)COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04983446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983446.